Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Cystic Fibrosis Test Aids in Parent and Newborn Screening

By LabMedica International staff writers
Posted on 17 Sep 2009
A new cystic fibrosis (CF) test screens potential parents to determine if they are carriers of CF-causing gene mutations and in confirmatory diagnostic testing in newborns and children.

The xTAG Cystic Fibrosis 39 kit (v2) detects 39 CF-causing gene mutations, including the 23 CF transmembrane conductance regulator (CFTR) gene mutations and four variants (polymorphisms) recommended by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG), as well as 16 additional CFTR gene mutations from human blood specimens. More...
The xTAG kit is flexible, offering physicians the ability to select the CFTR gene mutations for which they want to test, up to the entire panel of 39 CFTR gene mutations.

This flexibility is intended to allow laboratories to avoid having to use different platforms for various testing purposes, thus saving time and resources. Additionally--similar to the first-generation xTAG CF test (v1)--the new xTAG Cystic Fibrosis 39 kit v2 does not require reflex testing; all results are revealed and available for analysis at each run, if necessary. The protocol for testing has been streamlined to make the process faster and easy to use. The xTAG Cystic Fibrosis 39 kit (v2) is a product of Luminex (Austin, TX, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"The first FDA-cleared molecular diagnostic test for cystic fibrosis demonstrated Luminex's leadership in innovative CF testing. With this improved product, we focused on our customers' need to have a faster and easier to use IVD-cleared test with broad genetic mutation coverage,” said Patrick J. Balthrop, President and CEO of Luminex. "The xTAG Cystic Fibrosis 39 kit v2 gives doctors the ability to quickly, accurately and effectively screen potential parents for CF gene mutations and diagnose the disease early, which will assist in improving the health and quality of life of people with CF around the world.”

CF is a chronic inherited genetic disease in which the body produces thick, sticky mucus that can clog the lungs and affect the digestive system, and can have debilitating and potentially life-threatening consequences. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, of which over 1,500 have been identified to date. Late diagnosis of the disease is associated with chronic lung infections and compromised growth, whereas early detection and treatment has been shown to reduce therapeutic needs, lower rates of complications, and increase life expectancy.

Related Links:

Luminex




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.